MedPath

Comparison of Postoperative Nociception Between NOL-guided and Standard Intraoperative Analgesia Based on Fentanyl

Not Applicable
Completed
Conditions
Pain, Postoperative
Anesthesia
Allodynia
Postoperative Pain
Opioid Use
Nociceptive Pain
Analgesics, Opioid
Interventions
Registration Number
NCT03858621
Lead Sponsor
Victor Contreras, MSN
Brief Summary

Pain is defined as an unpleasant sensory and emotional conscious experience, associated with actual or potential tissue damage. Nociception is the sympathetic response to noxious stimuli during unconsciousness. The appearance of different forms of chronic pain results from sensitization of both peripheral and central neural circuits of pain, which involves inflammatory mechanisms both at a systemic level and specifically in the peripheric and central nervous system, as observed through elevation of specific neuroinflammatory mediators, such as MCP-1, IL-1, IL-1b, and IL-10. Clinically, this sensitization expresses as hyperalgesia and allodynia, which increase postoperative pain and morbidity, but also induce permanent modifications in the nociceptive system. These effects may be ameliorated by adequately adjusting intraoperative analgesia through use of nociception/analgesia balance monitors, of which Nociception Level Index (NOL) shows convenient characteristics and promising results from previous studies.

Objectives: The goal of our study is to assess the utility of NOL index monitoring against standard care for Fentanyl-based analgesia by measuring postoperative pain, sensorial thresholds and inflammatory markers related to nociception.

Hypothesis: The use of NOL index to guide the intraoperative analgesia will produce less postoperative pain, hyperalgesia, allodynia, and neuroinflammation.

Detailed Description

Methodology: In this RCT double-blinded study will invite to 100 patients aged between 18 and 50 years admitted for elective surgery that is planned to require general anesthesia, with fentanyl as the opioid of choice for intraoperative analgesia.

Each patient will be randomly allocated to one of two groups: the intervention group will be provided intraoperative analgesia guided by NOL values (n=50), and the control group will be provided standard intraoperative analgesia (n=50). To account for inter-personal variability, the NOL threshold value associated with nociceptive stimulation will be assessed on each patient at baseline condition with the Quantitative Sensory Testing (QST) and neuroinflammatory mediators MCP-1, IL-1, IL-1b, and IL-10 will be measured pre- and post-surgery in both groups. Opioid consumption and AVS will be assessed during the stay at the post-surgical care unit as a measurement of post-operative pain and will follow them until three months after surgery.

Statistical Analysis: Results will be expressed as means (±SD) or numbers (%). When indicated, 95% confidence interval (CI) will be calculated. A p-value \< 0.05 will be considered statistically significant.

Differences between groups on post-surgical opioid consumption, Δz-score of QST measurements, and serum biomarkers level will be analyzed with Student's T-test for unpaired samples. For analysis purposes, VAS scores will be grouped into three distinct categories: Mild (0-3), Moderate (4-6) and Severe (7-10) pain. Differences between groups will be analyzed with Chi-square test.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • ASA I-II
  • Elective abdominal surgery without a neuraxial block.
  • Over 2 horas.
  • Body Mass Index 18 - 30 kg/m2
Exclusion Criteria
  • Cardiac surgery
  • Cardiopathy
  • Arrhythmia or use of pacemakers.
  • Chronic Kidney disease (Plasma Crea >1 mg/dL).
  • Allergic to drugs of this study.
  • Opioids or Non-inflammatory drugs over 5 days for two weeks before surgery.
  • Neuropathies and dysautonomias.
  • Beta-blockers and other drugs that act at the level of the sympathetic system the month prior to surgery.
  • Chemotherapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
fentanyl NOL guidedfentanyl NOL guidedA bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
Primary Outcome Measures
NameTimeMethod
Consumption of IV fentanyl intra-operative in the NOL-guided group compared to the standard group.Intra-operative

Total consumption of fentanyl in mcg.

Consumption of opioid in the early postoperative in the NOL-guided group compared to the standard group.Postoperative Unit (2 hours)

Total consumption of morphine in mg.

Secondary Outcome Measures
NameTimeMethod
Pain Management Satisfaction in the NOL-guided group compared to the standard group.Postoperative (12 hours)

Pain Management Satisfaction Scale

1 to 5. 1 = Not satisfied at all. 5 = Completly satisfied One question

Inflammatory markers in the NOL-guided group compared to the standard group.Postoperative (12 hours)

Concentration in plasma of: MCP1 (pg/mL) , IL6 (pg/mL) , IL1b (pg/mL), IL10 (pg/mL)

Pain measured by Visual Analog Scale (VAS) in the NOL-guided group compared to the standard group.Postoperative Unit (Every 30 minutes per 2 hours)

Visual Analog Scale 0 to 10. 0 = no pain. 10 = worse pain Values to find out is less than 5-6

Sensorial thresholds in the NOL-guided group compared to the standard group.Postoperative Unit (2 hours)

QST (Quantitative Sensory Testing) is a valuable method for diagnosing peripheral nervous system disorders.

1. Thermal Testing

2. Mechanical test threshold

3. Mechanical pain threshold

4. Wind-up phenomenon

5. Vibration detection threshold

6. Pressure pain threshold

Persistent pain at three months in the NOL-guided group compared to the standard group.3 months after surgery

Brief Pain Inventory by telephone call

Trial Locations

Locations (1)

Victor Contreras

🇨🇱

Santiago, Región Metropolitana, Chile

© Copyright 2025. All Rights Reserved by MedPath